VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2014 | ASH 2014: Novel treatments for mantle cell lymphoma

Jia Ruan • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma Bortezomib Ibrutinib Lenalidomide

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses novel combination therapies that are currently being investigated in the clinic to address the unmet need in mantle cell lymphoma treatment. These therapeutic agents include bortezomib, lenalidomide, ibrutinib and rituximab.

More from Jia Ruan

2:48
ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)
Jia Ruan • 5 Dec 2014
4:38
ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 1)
Jia Ruan • 5 Dec 2014
4:03
Novel agent therapies are improving R/R PTCL outcomes
Jia Ruan
9:38
New agents and therapeutic options for T-cell lymphoma
Jia Ruan • 21 Oct 2021

Related Videos

3:01
Treating indolent and mantle cell lymphoma: results of the BRIGHT 5 year follow up study
Ian Flinn
1:07
MCL trials to watch out for at ASH 2019
Simon Rule
1:33
Developing mantle cell lymphoma treatment for further success
John Kuruvilla
1:15
Clinical impact of ATM and TP53 mutations in mantle cell lymphoma
Jitka Malčíková
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals